Leflunomide

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

Leflunomide in Previously Treated Metastatic Triple Negative Cancers

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma

Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease

Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies

Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer

CHronic Nonbacterial Osteomyelitis International Registry

IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy

Treatment Strategies for IgG4-RD Patients With Internal Organ Involvement

Leflunomide in Mild COVID-19 Patients

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations

Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders

Acupuncture Study on Rheumatoid Arthritis, Monitoring Microbiome and Blood